| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Apr, 2026 |
| Sales | 11,157,000 | 10,384,000 | 9,979,000 | 9,306,000 | 0 |
| Sales Growth | +7.44% | +4.06% | +7.23% | unch | unch |
| Net Income | 914,000 | 1,000 | 77,000 | 848,000 | 0 |
| Net Income Growth | +91,300.00% | -98.70% | -90.92% | unch | unch |
Sandoz Group Ag ADR (SDZNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sandoz Group AG develops, manufactures and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars and biotechnology manufacturing services and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Sandoz Group AG is based in Rotkreuz, Switzerland.
Fiscal Year End Date: 12/31